TMEM183A

Across TCGA pan-cancer cohorts, TMEM183A RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated TMEM183A data layer compared with 3 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TMEM183A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM183A expression acts as an unfavorable survival marker, although some lineages such as KIRC and STAD show a favorable association.

ACC, MESO, and KICH are the cancer types where TMEM183A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.172	0.721	<.001	135	view →
MESO	OS	Median	All	0.436	0.650	<.001	92	view →
KICH	OS	Quartile	All	0.793	1.000	.004	44	view →
LIHC	OS	Median	All	0.703	0.844	<.001	44	view →
KIRP	DFS	Median	II,III,IV	0.300	0.660	.007	43	view →
KIRC	DFS	Tertile	All	0.841	0.689	.002	25	view →
STAD	DFS	Quartile	II,III,IV	0.690	0.490	.018	25	view →
READ	DFS	Median	III,IV	0.367	0.667	.003	19	view →
ESCA	DFS	Quartile	III,IV	0.253	0.501	.006	19	view →
HNSC	DFS	Tertile	IV	0.690	0.539	.012	14	view →
SCLC	OS	Tertile	All	0.585	1.000	.018	12	view →
UVM	DFS	Median	III,IV	0.220	0.664	.020	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

TMEM183A–ACC (DFS)

Open the ACC breakdown →